Drug regulators have ordered pharmaceutical major Sun Pharma to halt eye drop production at its manufacturing facility located in Assam following the detection of quality compliance lapses, according to reports by Business Today and The 420.in.

The regulatory intervention follows quality control issues identified during compliance checks on eye drop products manufactured at the Assam unit. A report by The 420.in stated that regulators ordered a halt to eye drop manufacturing at the plant due to quality lapses. A separate report by Business Today stated that regulatory authorities ordered Sun Pharma to shut down the Assam facility over the eye drop quality lapses.

Details and Official Response Pending

Specific details regarding the precise nature of the quality lapses, including whether any specific batches were compromised or recalled from the market, have not been reported in the initial media coverage. The specific regulatory body responsible for issuing the order to Sun Pharma has also not been named in the reports.

Additional information regarding the total scope of the shutdown, its financial impact on the company, and the required compliance steps for resuming operations in Assam remains undisclosed. It has not yet been reported whether Sun Pharma has issued a formal statement or filed a response addressing the regulatory directives.

Sources

This report was prepared by the Vani24 news desk with AI assistance, based on reporting by the publications below.